PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer

Two new trials exploring this approach ― olaparib in the PROpel trial and niraparib in the MAGNITUDE trial –― had slightly different results.
Medscape Medical News

source https://www.medscape.com/viewarticle/968902?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost